Filing Analysis
💸 Securities Offering
Filed Aug 08, 2024
🟠 HIGH
Citrine Global, Corp. entered into a term sheet with X Group Fund of Funds Limited Partnership for a $250,000 investment in exchange for 25,000,000 units (stock + warrants) at a nominal price of $0.01 per unit. The company intends to use the proceeds primarily to fund required periodic filings.
🚩 Red Flags
- Extremely low share price ($0.01 per unit) indicates a highly distressed or shell-like valuation.
- Massive dilution: 25,000,000 shares for only $250,000 represents an effective price of $0.00001 per share.
- Use of proceeds is specifically to fund 'required periodic filings,' suggesting the company may be in danger of delisting or non-compliance due to missing reports.
- The inclusion of a consulting agreement for 25,000,000 shares suggests significant potential for further dilution and related-party influence.
📋 Key Facts
- Total investment amount: $250,000 via two tranches ($100k by Aug 31, 2024; $150k by Sept 30, 2024).
- Consideration: 25,000,000 units, each consisting of one share of common stock and one warrant to purchase an additional share at $0.01.
- X Group receives the right to recommend two director nominees meeting US Exchange standards upon completion.
- A consulting agreement involving 25,000,000 shares is contemplated subject to investment completion.
- Proceeds are earmarked for preparing and filing required periodic SEC filings.
🚪 Officer Departure
Filed Feb 23, 2024
⚪ LOW
Citrine Global, Corp. announced the resignation of Director Doron Birger from the Board of Directors, effective February 22, 2024.
📋 Key Facts
- Doron Birger resigned from the Board of Directors on February 22, 2024.
- The resignation was not due to any disagreement with the Company regarding operations, policies, or practices.
- Mr. Birger expressed interest in continuing to work with the Company in an advisory or consulting capacity.
💸 Securities Offering
Filed Feb 15, 2024
🟠 HIGH
Citrine Global Corp. entered into a $63,250 promissory note with 1800 Diagonal Lending LLC on February 9, 2024. The agreement includes significant debt-to-equity conversion features at a steep discount to market price.
🚩 Red Flags
- Highly dilutive conversion feature (39% discount to lowest price)
- Significant share reserve (over 51 million shares) relative to typical micro-cap structures
- Lender has unilateral right to increase the number of reserved shares
- High default interest rate of 22%
📋 Key Facts
- Principal amount of Note: $63,250
- Gross proceeds received by Company: $55,000 (due to original issue discount)
- Total payback to Lender: $72,737.00 via nine payments of $8,081.89
- Interest rate: 15% per annum; Default interest: 22% per annum
- Maturity date: November 15, 2024
- Conversion feature: Lender can convert debt to common stock at a price equal to 61% of the lowest trading price during the 20 trading days prior to conversion (a 39% discount).
- Shares reserved for potential conversion: Initially 51,844,262 shares.
🛒 Asset Acquisition
Filed Jan 05, 2024
🟠 HIGH
Citrine Global, Corp. consummated a Share Purchase and Option Agreement to acquire a 19% equity stake in iBOT Israel Botanicals Ltd. for $10 million via the issuance of 70,370,370 shares at $0.027 per share.
🚩 Red Flags
- Massive dilution: Issuance of over 70 million shares at a very low price ($0.027) represents significant dilution for existing shareholders.
- Concentrated Director Compensation: Large grants of restricted shares to directors (e.g., CFO received 14.7M shares) immediately following a major acquisition.
- Potential cash drain: The option to increase iBOT stake to 51% requires the company to fund iBOT's operating budget for 24 months.
📋 Key Facts
- Acquired 19% equity stake in iBOT Israel Botanicals Ltd. on December 31, 2023.
- Consideration: Issuance of 70,370,370 shares of Citrine Global common stock.
- Share price used for calculation: $0.027 per share (based on 30-day high closing price).
- The transaction valuation was based on a discounted pre-company valuation by an independent third party.
- Company holds an option to increase iBOT stake to 51% through June 30, 2024 via shares and cash.
- Includes a 'no-shop' clause for the duration of the option period.
- Board granted restricted shares to directors: Ilanit Halperin (14.7M), David Kretzmer (7.525M), and Doron Birger (916,230).
Disclaimer: This analysis is generated by AI and is for informational purposes only.
It does not constitute financial advice, investment recommendations, or an offer to buy or sell securities.
Always review the original SEC filings and consult a financial advisor before making investment decisions.